Mesenchymal Stem Cell (Acute Respiratory Distress Syndrome – STI 8282)
Sorrento is entering Phase I Trial of Mesenchymal Stem Cell (MSCs) for patients suffering from Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19, which have been cleared by the FDA.
The primary objective of the Phase 1 study is to evaluate the safety of intravenous infusion of allogeneic adipose stem cells in patients with COVID-19 and in respiratory distress. The secondary objective is to evaluate a set of safety and efficacy outcome variables to give guidance regarding the risk/benefit ratio in patients with COVID-19 respiratory distress.
Stem cells have been demonstrated to support resolution of symptoms in multiple disease settings and have the potential to reduce the long-term effects associated with pulmonary tissue damage for these patients. MSC represent a treatment modality with high potential to help in the fight against COVID-19 as a stand-alone therapy or in synergy with other product candidates in Sorrento’s pipeline, including small molecules (abivertinib or salicyn-30) and neutralizing antibodies (STI-1499 or STI 2020).